Dr. James A. Mcguire, D.O. Pain Medicine - Interventional Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Ogden Ave, Aurora, IL 60504 Phone: 630-978-4860 |
Dr. John L. Bertolozzi, D.O. Pain Medicine - Interventional Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Ogden Ave, Aurora, IL 60504 Phone: 630-978-4860 |
Ramesh Bathina, MD Pain Medicine - Interventional Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 1315 N Highland Ave # 105, Aurora, IL 60506 Phone: 630-966-9999 Fax: 630-859-2378 |
Dr. Brian A. Barnett, M.D. Pain Medicine - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Ogden Ave, Aurora, IL 60504 Phone: 630-978-4860 |
Dr. Hung Shing Tsang, M.D. Pain Medicine - Interventional Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 1315 N Highland Ave, Suite 203, Aurora, IL 60506 Phone: 630-906-1800 Fax: 630-906-9860 |
Dr. Quang Duy Pham, D.O. Pain Medicine - Interventional Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Ogden Ave, Aurora, IL 60504 Phone: 630-978-4860 |
News Archive
About half a century ago, organized medicine and the hospital industry in this country struck a deal with Congress that in retrospect seems as audacious as it seems incredible: Congress was asked to surrender to these industries the keys to the United States Treasury. In return, the industries would allow Congress to pass a 1965 amendment to the Social Security Act .... We have come to know it as Medicare.
Giving patients steroids at the time of heart surgery does not improve health outcomes and appears to put them at greater risk of having a heart attack in the days following surgery, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
The United States Food and Drug Administration approved EnteroMedic's VBLOC vagal blocking therapy, delivered via the Maestro System, which is the first medical device approved for obesity treatment that targets the nerve pathway between the brain and the stomach.
Contrary to the perception of some patients and physicians, there is no evidence that brand-name drugs are clinically superior to their generic counterparts, according to an article in the December 3 issue of JAMA, which examined studies comparing the effectiveness of generic vs. brand-name drugs for treating cardiovascular diseases.
Data from a small cohort published OncoTargets and Therapy today shows that the Paradigm Cancer Diagnostic Test (PCDx) performed better than Foundation Medicine's FoundationOne test across a number of key clinical variables, including turnaround time (TAT) and clinically actionable biomarker targets.
› Verified 4 days ago